US patent 7,256,272 covers composition of matter claims for a CD63 targeting antibody and clone. Arius says that the CD63 targeting antibody has the potential to recruit the body’s own defense system to attack cancer and has been shown to prevent tumor growth and enhance survival in breast cancer models.
US Patent 7,256,271 contains claims on a targeting antibody and clone composition of matter. Carcinoembryonic antigen (CEA) is a broadly expressed tumor marker and Arius’s CEA targeting antibody has demonstrated potent anti-tumour activity in colon and breast cancer models, according to the company.